Slide 1: Licence for Global Markets 2004
Licence “for Global Markets. eee 2004
Slide 2: Founded 1999; Melbourne based
Founded 1999; Melbourne based. i l Diversified business model: oe Diagnostics - = revenue ® producing Therapeutics "Therapeutic programs: ls ie Alzheimer’s Disease” Parkinson’ S Disease o att | “Experienced & successful management B board uv ) a : "Successful listing of 14m shares EE cogstate alg Tr
Slide 3: Diversified Business Model
Diversified Business Model repeal Diagnostics Dx: Selling Diagnostic: Tests Hy + ir Computerized cognitive (brain) function tests tite ] _ Tests and results distributed via the internet “Selling | in 4 Markets | oo 1 CogState Therapeutics Rx: Developing CNS Drugs | Finds and | in- -licenses preclini
Slide 4: CogState Diagnostics Products
Do the twa face-up cards match any of the pairs above (in any order)? YES = K hay NO= D key Press Tab to skip to next task. CogState Dia ynostics Products _Cogstate | a i.
Slide 5: What is CogState Diagnostics?
“What is CogState Diagnostics? 7 Measures change in 1 cagnitive state: . Attention, memory and executive functions _ | Repeatable with minimal practice effects __ Beret | Language, allure, educational: history neutral Plttittrte | 24 hour access - PiSttritt ere : | Portable PECLEEE _ Automatic repor
Slide 6: Computer Testing Using Playing Card Stimuli
Computer Testing Using Playing ¢ Card Stimuli (culture neutral, minimal language, game-like) fferent rules = different tests = assessment of different cognitive functions ; Is it there?” oo (detecting) a 7 Is it red 2 (identifying) is it the same > (matching) _ ' Was it there 2 (remembering) i og Me
Slide 7: Scalable Distribution Via the Internet
Scalable Distribution Via the Internet internet _ download : (Coastate load CogState oftware from CD | test patient vite email to. ti | \ automatic | CogState / report. oe CogState af, generation
Slide 8: The complete concussion management system
Tha complete concussion management system Change from Baseline test The follwing tires graphs stow changes in aac of he faur Gopspertperemiance darren between the curren: tast [¥ Pp 202, 42apm) ated thes bawling esi 2%G Real 200%, OLc-17aMvs The shaded ares inizabas thes veel ange eT Rerroimance cha
Slide 9: Significant Global Markets
Significant Global Markets. gState Clinical: Pharma clinical trials. ase I; Phase II-III; Phase v- enultipis tests) - | 150,000 people 7 ogSport: : | 30m US children cussion Management. test for contact sports. 122m > 50y 2050 ual Screening test for Early Alzheimer’ S Disease : CogState af, | 4.5m U
Slide 10: Validation of Diagnostics by Significant Users
"Validation of Diagnostics by Significant Users CogState Clin cal |CogSport Pfizer Pharmaceuticals | Johnson and Johnson © Quaker Oats 7 NASA Space Station Research US Universities: tT ee e Johns Hopkins - ‘Duke University » Yale Medical School Many other universities Center for. Disease Control (us
Slide 11: Product Launch Activities
Product Launch Activities —|CogHealth nion projects (duty of care) ‘| Endorsement of AlzAssoc Pt Drug company sponsorships tributor agreements —_| Deal with HCN (Medical Director) : | Various distribution channels sf : CogState ef, 7 11
Slide 12: CogHealth: Market Need for an Early Alzheimer's Test
CogHealth: ‘Market Need for an Early Alzheimer’ S Test Need for a brain weight- machine | = Annual tests: mammogram, PSA, cholesterol . No brain check for early alzheimer’ s disease 4 1 i Most cases go un- diagnosed until advanced _ ae Living with gradual decline e.g. acromegaly | a a : : CogState a
Slide 13: oe Ga
oe Ga a) : a | LS LD i 4 ih ae / Ly a yy a es y
Slide 14: What is CogState Therapeutics?
| What is CogState Therapeutics? Two drug de elopment platform technologies Several other rograms in diligence. review ontinuous diligence o of new technologies AIL products: ensed at preclinical stage 1 . Alzheimer’s sease & Parkinson’ s Disease : . Large unmet linical global market need | _Cogstte
Slide 15: Research
Research Stage | | Laboratory OBS years . * CagState identifies opportunity, conducts diligence, examines strength Of FP evaluates compatitive advantages in market analysis. Project manages Project manages Project manages Outsourced Outsourced Qutsourced Lead Initial Efficacy optimisation | human. h
Slide 16: Alzheimer's Disease: Targeting Large Unmet Clinical Markets
Alzheimer’s Disease: s Rate of tin 15 @ age 65y =. Rate. of 1 in 2 @ age B5y u 8 million people. worldwide ett tee : tat a annual sales of existing. drugs re Rate of 3in 100 eae at Rate of 3.6 million people worldwide | ae US$. ib annual ‘sal les of existing drugs 7 Tit : CogState af, Targeting Larg
Slide 17: CogState Treatments for AD and PD: Cog0192
CogState treacrents: for AD. ane PD: Project Cog0192 for Alzheimer’ S ll : : Preclinical early stage series of drug structures He fr Licensed from Taisho Pharmaceuticals ee Research contracts with U. Washington, US. World- wide rights excluding Japan & China» Mechanism : via Angiotensin (AT4) recept
Slide 18: CogState Treatments for AD and PD: Cog0392
CogState 7 Treatments for AD and PD: Project Cog0392 for Parkinson’s Disease . m Pre-clinical drug molecule : ‘Worldwide rights Licensed from Brain Research, Israel (Prof, Yehuda) Target oral administration and BBB transit Extensive animal data in Parkinson’s models _ : Tyrosine is a precursor of Do
Slide 19: CogState Therapeutics v CogState Diagnostics
- CogState Therapeutics v CogState Diagnostics - ————————————— a oo Lg. _ a Hs ae a aie L a a CS vie Ae oe - 7 ae a Lo - CogState ef, ab
Slide 20: “_Cogstate | a i.
“_Cogstate | a i.
Slide 21: Management Team
fanagement Team o esive; Start-up > » Big Company Experience; » Dr. Peter Bick MD MBBS MBA ABPN, CEO. ree «Influence Inc, Skagus Group, NVC, Quintiles Tt . Prof. Paul Maruff, PhD MPsych, CSO_ 7 _« MHRI, La Trobe University. ttt . Dr. David Darby MBBS FRACP PhD, CMO. oe MERI, Harvard, U- Melbourne Se
Slide 22: Board of Directors
Martyn Myer, BE MESc MSM - Coles Myer (CHAIRMAN) Dr. Peter Bick, MD MBBS. MBA ABPN, CEO. Dr. Geoff Brooke, MBBS MBA - GBS” Ventures | eee Dr. David Darby, MBBS FRACP PhD, Founder CMO rr Richard d Moran Chiol, MIBiol, , PIP RCPath — Glaxo Smith Kl cline. Tirte _Cogstate af, a : a
Slide 23: eae OOS
eae OOS — Cogstate mg
Slide 24: i $123,980 TT a
30.6.02 30.6.03. 731.12.03. | - i $123,980 TT a $302,378 /$133,450 a $662, 763 ($613,138 $1, 094, 408. ($1,331,244 | $1,060,716 | 7 $907, 027 ny ‘|$e09,231 Inc in op costs | | 1: ice 338 670) 7 ($1,327 27) |($876,347) a $370, 830 it $59) 833 1 $351,406 | oo “Cogstate 7 24 —
Slide 25: Use of funds
Diagnostics Sal jes and Marketing - | [#3600958 itt roject i in Alzheimer’ S Disease 7 -roject 2 in Parkinson’ 5 Disease : Te 898,633 | ) $227,700 Research and Development Overhead TTT $ 186 720 tr : Management and ‘Administration Tr z imate TETTEL Cost of the offer ||$ 840,600 Total ]$ 7,000,000 0
Slide 26: Milestones
ue a sy a a ae ai: Milestones — — Cogstate mg
Slide 27: Milestones: Next 18-24 Months
Milestones: Next 18-24 Months gState Diagnostics Dx: Selling Diagnostic Tests CogState: Preferred provider deal with a major drug | company — 7 New customers in pharmaceutical and biotech companies | Multiple distribution deals worldwide : sogSafe: - Distributor deal Australia oe 7 Teetttete rere Co
Slide 28: CogState Announces Major Deal with Pacific Northwest Biotechnology
CogState Announces’ Major Deal with Pacific orthwest Biotechnology, Inc. ne acific Northwest, Biotechnology. isa US company in Washington ir inded by. Prof. Joe Harding and Prof. Jay Wright. : 7 fessors. Harding and Wright first characterised the ATS receptor “receptors are expressed in the part of.